60
Participants
Start Date
May 1, 2023
Primary Completion Date
October 31, 2024
Study Completion Date
October 31, 2024
K-877 0.2 mg/day (once daily)
K-877 0.2mg tablet
K-877 0.4 mg/day (once daily)
K-877 0.2mg tablet
Placebo (once daily)
Placebo tablet
Nakayama Clinic, Aichi
Kohnodai Hospital, National Center for Global Health and Medicine, Chiba
Tashiro Endocrinology Clinic, Fukuoka
Central Japan International Medical Center, Gifu
NTT Medical Center Sapporo, Hokkaido
Tsukuba Medical Center Foundation Tsukuba Medical Center Hospital, Ibaraki
Yokohama Minami Kyosai Hospital, Kanagawa
Kumamoto University Hospital, Kumamoto
Medical Corporation LONGWOOD Maeda Clinic, Osaka
OCROM Clinic, Osaka
Rinku General Medical Center, Osaka
Koshigaya Municipal Hospital, Saitama
Saitama Medical University Hospital, Saitama
Affiliated CENTRAL CLINIC of Higashiyamato Hospital, Tokyo
Fukuwa Clinic, Tokyo
Juntendo University Hospital, Tokyo
Medical Corporation Chiseikai Tokyo Center Clinic, Tokyo
Mishuku Hospital, Tokyo
Seiwa Clinic, Tokyo
ToCROM Clinic, Tokyo
Tokyo Heart Summit Tokyo Heart Rhythm Hospital, Tokyo
Tokyo-Eki Center-building Clinic, Tokyo
Kowa Company, Ltd.
INDUSTRY